Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits specific cytotoxic T-cell immune responses. In this phase II study, dendritic cells transfected with wild-type TP53 (vaccine) were administered to patients with extensive-stage small cell lung cancer after chemot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappori, Alberto A., Williams, Charles C., Gray, Jhanelle E., Tanvetyanon, Tawee, Haura, Eric B., Creelan, Ben C., Thapa, Ram, Chen, Dung-Tsa, Simon, George R., Bepler, Gerold, Gabrilovich, Dmitry I., Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426813/
https://www.ncbi.nlm.nih.gov/pubmed/30591959
http://dx.doi.org/10.1007/s00262-018-2287-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426813/
https://www.ncbi.nlm.nih.gov/pubmed/30591959
http://dx.doi.org/10.1007/s00262-018-2287-9

Ejemplares similares